Assess drug safety and predict adverse effects early in the pipeline with our advanced organoid and organ-on-a-chip toxicity screening platforms, designed to reduce attrition rates and support safer candidate selection.
- Introduction
- Platform
- Capabilities
- Features
- Applications
Human-Relevant Platforms for In Vitro Toxicity Screening
Drug-induced toxicity remains a primary cause of late-stage clinical trial failures and post-market drug withdrawals. Traditional 2D cell cultures and animal models often lack the physiological relevance required to accurately predict human clinical responses, leading to translational gaps.
Our organoid and organ-on-a-chip technologies provide a bridge between traditional in vitro assays and in vivo human physiology. By mimicking native tissue architecture, dynamic microenvironments, and complex intercellular crosstalk, these microphysiological systems (MPS) deliver highly predictive, reliable data for early toxicity detection and mechanistic safety evaluation.
Our Toxicity Screening Platform
3D Human Organoids
Derived from human primary cells or stem cells, these 3D models replicate tissue-specific cellular diversity, offering an accurate platform for assessing tissue-level toxicity and cell viability.
Organ-on-Chip Systems
Microfluidic platforms that introduce physiological shear stress and dynamic flow, crucial for evaluating acute and chronic toxic responses under human-relevant biomechanical conditions.
Multi-Organ-on-Chip
Interconnected models that allow for the evaluation of systemic toxicity and the adverse effects driven by secondary drug metabolites generated in upstream organs (e.g., liver).
Multiplexed Bioanalysis
Integrated High-Content Screening (HCS), biomarker quantification, and omics profiling to provide a comprehensive understanding of the mechanisms of toxicity.
Comprehensive Toxicity Assay Capabilities
Hepatotoxicity
Utilizing human liver organoids and liver-on-chip models with stable CYP450 metabolic activity, we accurately predict Drug-Induced Liver Injury (DILI). Key assessments include:
- Hepatocyte viability and mitochondrial toxicity
- Drug-induced cholestasis and steatosis
- Metabolite-mediated toxicity
Cardiotoxicity
Our iPSC-derived cardiac organoids and heart-on-a-chip platforms enable early detection of structural and functional cardiac damage. Key assessments include:
- Electrophysiological alterations (e.g., arrhythmia risk)
- Contractility changes and beating kinetics
- Cardiomyocyte viability and structural integrity
Gastrointestinal (GI) Toxicity
We simulate the human intestinal epithelium using intestinal organoids and gut-on-chip systems to evaluate local drug-induced mucosal damage. Key assessments include:
- Epithelial barrier disruption and tight junction integrity
- Mucosal inflammation and cytokine release
- Intestinal cell viability
Nephrotoxicity
Our kidney organoids and tubule-on-a-chip models replicate renal filtration barriers to assess drug clearance-related toxicity. Key assessments include:
- Proximal tubule damage and cell death
- Alterations in renal barrier function
- Early kidney injury biomarkers (e.g., KIM-1, NGAL)
Advantages of Our Toxicity Platforms
-
Enhanced Translational Value
Human-derived models circumvent species-specific differences, offering a higher predictive value for clinical outcomes than traditional animal models. -
Mechanistic Insights
Advanced readout capabilities allow for in-depth investigation into the pathways and mechanisms driving drug-induced cellular injury. -
Physiological Microenvironments
Incorporation of fluid flow, shear stress, and co-culture systems reliably mimics the in vivo tissue context. -
Flexible & Scalable Assays
From medium-throughput early safety screening to detailed late-stage mechanistic investigations. -
Ethical Alternative
Reduces reliance on in vivo animal testing in alignment with the 3Rs (Replacement, Reduction, and Refinement) principles.
Applications in Drug Discovery
Our comprehensive toxicity screening services are suitable for various research and development stages:
- Early safety screening and lead optimization
- De-risking of compounds prior to IND-enabling studies
- Mechanistic investigation of specific organ toxicities
- Assessment of environmental toxins and chemical safety
- Evaluation of novel modalities (e.g., biologics, nanoparticles)
Advance your drug pipeline with predictive safety screening
Our experienced scientific team offers customized assay design and expert consultation tailored to your specific safety concerns.
Partner with us to identify potential toxicities early and proceed with confidence.
Need advice on the most appropriate model for your compound? Contact us for a free technical consultation.
Products
Online Inquiry